TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01902394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grains
Description: Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Refined grains
Description: Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
Study: NCT02962752

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackadder Juice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00688571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Melody Transcatheter Pulmonary Valve
Description: Transcatheter valve implantation into a RV-PA conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs intervention
Study: NCT00838539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Study: NCT02642042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT01169558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg bevacizumab administered intravenously every 2 weeks or 7.5 mg/kg bevacizumab administered intravenously every 3 weeks according to the standard chemotherapy regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine-based Chemotherapy
Description: Fluoropyrimidine-based chemotherapy administered according to standard of care.
Study: NCT01705574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF
Description: 150/150/200/300 mg FDC tablet administered orally with food once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF
Description: 150/150/200/300 mg FDC tablet administered orally with food once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV
Description: 300 mg capsule administered orally with food once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: 300 mg capsule administered orally with food once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RTV
Description: 100 mg tablet administered orally with food once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: 100 mg tablet administered orally with food once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: 200/300 mg tablet administered orally with food once daily
Study: NCT03288207

Intervention type: DEVICE
Group type: OTHER
Intervention: Bluetooth-enabled glucometer
Description: Bluetooth-enabled glucometer
Study: NCT01705574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: 200/300 mg tablet administered orally with food once daily
Study: NCT03288207

Intervention type: DEVICE
Group type: OTHER
Intervention: Bluetooth-enabled glucometer
Description: Bluetooth-enabled glucometer

Intervention type: DEVICE
Group type: OTHER
Intervention: Bluetooth-enabled scale
Description: Bluetooth-enabled scale

Intervention type: DEVICE
Group type: OTHER
Intervention: Bluetooth-enabled scale
Description: Bluetooth-enabled scale

Intervention type: DEVICE
Group type: OTHER
Intervention: Global Positioning System (GPS) Device
Description: Global Positioning System (GPS) Device

Intervention type: DEVICE
Group type: OTHER
Intervention: Global Positioning System (GPS) Device
Description: Global Positioning System (GPS) Device

Intervention type: DEVICE
Group type: OTHER
Intervention: Step it Up mobile app
Description: Step it Up mobile app

Intervention type: DEVICE
Group type: OTHER
Intervention: Step it Up mobile app
Description: Step it Up mobile app
Study: NCT01705574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E/C/F/TDF Placebo
Description: Tablet administered orally with food once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV Placebo
Description: Tablet administered orally with food once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV Placebo
Description: Capsule administered orally with food once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF Placebo
Description: Tablet administered orally with food once daily
Study: NCT04562896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Carbon Fiber Dynamic Orthosis (CDO)
Description: The custom carbon fiber dynamic orthoses will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
Study: NCT01705574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablet administered orally with food once daily
Study: NCT01660594

Intervention type: OTHER
Intervention: CT calcium scoring
Description: CT Calcium scoring was performed in the patients as an imaging test in addition to the traditional assessment on the same day of patients attending the chest pain clinic on the first visit. This was performed with standard protocol and the absolute calcium score was calculated.
Study: NCT00294047

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Subjects were planned to receive three doses of the control vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
Study: NCT01066598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d
Study: NCT03649763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: lidocaine 1%, distal ( ulnar and medial nerve): 6ml/nerve , 12m total

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 0.5%,distal ( ulnar and medial nerve): 6ml/nerve , 12m total

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 0.5%,distal ( ulnar and medial nerve): 6ml/nerve , 12m total

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: lidocaine 1%, distal and proximal ( ulnar and medial nerve): 3ml/nerve , 12m total
Study: NCT04584749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Iv
Description: 2% lidocaine or 0.9% physiological saline will be used as placebo, and it will be administered as a bolus during anesthetic induction equivalent to 1.5 mg / kg of lidocaine. After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine.~20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing 2% Lidocaine .
Study: NCT04584749

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine Iv
Description: 2% lidocaine or 0.9% physiological saline will be used as placebo, and it will be administered as a bolus during anesthetic induction equivalent to 1.5 mg / kg of lidocaine. After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine.~20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing 2% Lidocaine .
Study: NCT01420978

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSF Diversion
Description: CSF drainage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSF Diversion
Description: CSF drainage
Study: NCT04626778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peroxyl Mouthwash
Description: Mouthwash

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Mouthwash
Description: Mouthwash
Study: NCT03073057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Description: 2 inhalations as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Description: 2 inhalations as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Description: 2 inhalations as a single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Charcoal
Study: NCT03073057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Charcoal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Charcoal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Charcoal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbuhaler
Description: 2 inhalations as a single dose
Study: NCT02011763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avaxim 80U Pediatric: Inactivated Hepatitis A Virus
Description: 0.5 mL, Intramuscular (2 injection 6 months apart)
Study: NCT01732211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD 0360324
Description: 100 mg Q2W or 150 mg Q2W via intravenous infusion based on protocol determined dose escalation/de-escalation criteria; 12 weeks Active Therapy;

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline for injection
Description: normal saline Q2W via intravenous infusion for 12 weeks
Study: NCT01319370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil
Description: 1 g of 5% Minoxidil topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle of 5% Minoxidil topical foam
Description: 1 g of vehicle topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
Study: NCT02843607

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
Study: NCT00731536

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. Medical records of patients with the diagnosis of HSTCL in the PALGA database will be analyzed.
Study: NCT02159404

Intervention type: BIOLOGICAL
Intervention: Immunotherapy
Study: NCT03338023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus®
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study: NCT01168180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Thai massage
Description: The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound therapy and hot pack
Study: NCT02659228

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: EEG recording
Description: EEG recording with anesthetic (DIPRIVAN)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG recording
Description: EEG recording with anesthetic (DIPRIVAN)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG recording
Description: EEG recording with anesthetic (DIPRIVAN)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthetics, Intravenous
Description: The participant will receive an intravenous infusion of propofol (DIPRIVAN Injectable Emulsion USP 1%, AstraZeneca).
Study: NCT03489525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Escalation, MEDI2228, ADC (antibody drug conjugate)
Description: Single agent MEDI2228 will be administered to adult subjects with R/R MM. The study aims to evaluate up to 9 planned, sequentially ascending main dose levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Expansion, MEDI2228, ADC (antibody drug conjugate)
Description: Adult subjects with R/R MM with measurable disease will be enrolled in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase.
Study: NCT02643979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 100mg of Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 1mL of saline
Study: NCT01189773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen and codeine
Description: ibuprofen: 10 mg/kg (max = 600 mg), codeine: 1 mg/kg (max = 60 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ibuprofen and codeine
Description: ibuprofen: 10 mg/kg (max = 600 mg), codeine: 1 mg/kg (max = 60 mg)
Study: NCT01835756

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia MLS
Description: The Erchonia® MLS contains 10 independent diodes, each emitting 17 milliwatts (mW), 635 nanometers (nm) of red laser light. The Erchonia MLS is applied to the lower back and hips area for 15 minutes per treatment administration, 6 times across 3 weeks, 2 times per week.
Study: NCT03650504

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Above Artery Catheter Placement
Description: Nerve catheter placed between superficial femoral artery and sartorial muscle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Between Artery and Vein Placement
Description: Nerve catheter placed between superficial femoral artery and femoral vein
Study: NCT02639676

Intervention type: OTHER
Intervention: Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections

Intervention type: OTHER
Intervention: Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections
Study: NCT00987415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: allopurinol
Description: Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
Study: NCT00795730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSA-789

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00575679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivational interview
Description: The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
Study: NCT02320578

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Laparoscopy
Description: 3D Laparoscopy approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Laparoscopy
Description: Standard laparoscopy approach
Study: NCT02509962

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Slow sodium tablets
Description: 6 g sodium chloride per day over 14 days
Study: NCT02070432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUZ11
Description: LUZ11 i.v. administration followed by laser light irradiation
Study: NCT03603132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hetrombopag Olamine
Description: 7.5mg in each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hetrombopag Olamine
Description: 7.5mg in each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hetrombopag Olamine
Description: 7.5mg in each cycle
Study: NCT00322114

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lycopene
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lycopene
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT01532661

Intervention type: OTHER
Intervention: observational study
Description: data collected by investigators
Study: NCT05821543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin+sibutramine
Description: 1 tablet (850 mg + 10 mg) once per day in the morning, without chewing and followed with a glass of water, during meals, for 180 days. At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit1 (Day 1), the zero dose was increased to 1 tablet (850 mg + 15 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sibutramine+ microcrystalline cellulose
Description: 1 capsule (10 mg + 158.5 mg) once per day in the morning, without chewing and followed with a glass of water, during meals for, 180 days.At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit 1 (Day 1), the zero dose was increased to 1 capsule (15 mg + 153,5 mg)
Study: NCT03469310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 500Mg Cap
Description: non-narcotic medication first with narcotic as second choice
Study: NCT01835756

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: The Placebo Laser has the same appearance and administration application as the Erchonia MLS but does not emit any therapeutic light.
Study: NCT02000037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IR Reflexotherapy
Description: 18 IR reflexotherapy sessions :~* Once a week for 12 weeks at the beginning of the study~* Once a week for 3 weeks, 9 months after the beginning of the study~* Once a week for 3 weeks, 15 months after the beginning of the study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IR Reflexotherapy
Description: 18 IR reflexotherapy sessions :~* Once a week for 12 weeks at the beginning of the study~* Once a week for 3 weeks, 9 months after the beginning of the study~* Once a week for 3 weeks, 15 months after the beginning of the study

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary care
Description: Dietary consultation 1, 2, 3, 6, 9, 12, 15 and 18 months after the beginning of the study
Study: NCT03469310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol #3 Oral Tablet
Description: Narcotic medication first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: non-narcotic medication first with narcotic as second choice
Study: NCT03233048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORBERA™ Intragastric Balloon
Description: The balloon will be inserted into the stomach and inflated, and will remain in place for 6 months, after which the device will be removed.
Study: NCT03940885

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinea plane block group
Description: Which will receive ultrasound-guided erector spinea plane block bilaterally and the local anesthetic injected will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: Which will receive ultrasound-guided Transversus Abdominis plane block bilaterally and the local anesthetic used will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: this group will receive only standard general anesthesia
Study: NCT03845283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce excess calories and gradually increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce excess calories and gradually increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce excess calories and gradually increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce excess calories and gradually increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce excess calories and gradually increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce excess calories and gradually increase physical activity.